Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.

Mol Immunol. 2007 Mar;44(8):1935-43. Epub 2006 Nov 2.

PMID:
17083975
2.

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.

Haagen IA.

Leuk Lymphoma. 1995 Nov;19(5-6):381-93. Review.

PMID:
8590837
3.

Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.

Stieglmaier J, Benjamin J, Nagorsen D.

Expert Opin Biol Ther. 2015;15(8):1093-9. doi: 10.1517/14712598.2015.1041373. Epub 2015 May 13. Review.

PMID:
25971805
4.

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Wu J, Fu J, Zhang M, Liu D.

J Hematol Oncol. 2015 Sep 4;8:104. doi: 10.1186/s13045-015-0195-4. Review.

5.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.

PMID:
19455460
6.

RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.

McAleese F, Eser M.

Future Oncol. 2012 Jun;8(6):687-95. doi: 10.2217/fon.12.54. Review.

PMID:
22764766
7.

Recombinant bispecific antibodies for cancer therapy.

Kontermann RE.

Acta Pharmacol Sin. 2005 Jan;26(1):1-9. Review.

8.

Bispecific T-cell engaging antibodies for cancer therapy.

Baeuerle PA, Reinhardt C.

Cancer Res. 2009 Jun 15;69(12):4941-4. doi: 10.1158/0008-5472.CAN-09-0547. Epub 2009 Jun 9. Review.

9.

BiTEs: bispecific antibody constructs with unique anti-tumor activity.

Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA.

Drug Discov Today. 2005 Sep 15;10(18):1237-44. Review.

PMID:
16213416
10.

[Bispecific antibodies: what future?].

Pèlegrin A, Robert B.

Med Sci (Paris). 2009 Dec;25(12):1155-8. doi: 10.1051/medsci/200925121155. Review. French.

11.

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.

Zimmerman Z, Maniar T, Nagorsen D.

Int Immunol. 2015 Jan;27(1):31-7. doi: 10.1093/intimm/dxu089. Epub 2014 Sep 19. Review.

PMID:
25239133
12.

Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R.

Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Review.

PMID:
22940266
13.

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Nagorsen D, Baeuerle PA.

Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Review.

PMID:
21419116
14.

Alternative molecular formats and therapeutic applications for bispecific antibodies.

Spiess C, Zhai Q, Carter PJ.

Mol Immunol. 2015 Oct;67(2 Pt A):95-106. doi: 10.1016/j.molimm.2015.01.003. Epub 2015 Jan 27. Review.

15.

Recombinant bispecific antibodies for cellular cancer immunotherapy.

Müller D, Kontermann RE.

Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Review.

PMID:
17694444
16.

Targeting T cells to tumor cells using bispecific antibodies.

Frankel SR, Baeuerle PA.

Curr Opin Chem Biol. 2013 Jun;17(3):385-92. doi: 10.1016/j.cbpa.2013.03.029. Epub 2013 Apr 25. Review.

PMID:
23623807
17.

Current perspectives of bispecific antibody-based immunotherapy.

Talac R, Nelson H.

J Biol Regul Homeost Agents. 2000 Jul-Sep;14(3):175-81. Review.

PMID:
11037049
18.

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

Goebeler ME, Bargou R.

Leuk Lymphoma. 2016 May;57(5):1021-32. doi: 10.3109/10428194.2016.1161185. Epub 2016 Apr 6. Review.

PMID:
27050240
19.

Generation of bispecific and tandem diabodies.

Kipriyanov SM.

Methods Mol Biol. 2002;178:317-31. Review. No abstract available.

PMID:
11968501
20.

Diabodies: molecular engineering and therapeutic applications.

Wu C.

Drug News Perspect. 2009 Oct;22(8):453-8. Review.

PMID:
20016854

Supplemental Content

Support Center